-
Subject Areas on Research
-
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.
-
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
-
A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia.
-
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
-
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
-
Adherence to hydroxyurea therapy in children with sickle cell anemia.
-
Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease.
-
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.
-
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.
-
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.
-
Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.
-
Caring for patients with sickle cell disease in North Carolina.
-
Cell cycle-dependent expression of thyroid hormone receptor-beta is a mechanism for variable hormone sensitivity.
-
Chemical Modulation of Endocytic Sorting Augments Adeno-associated Viral Transduction.
-
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
-
Comparative transcriptome analysis reveals novel roles of the Ras and cyclic AMP signaling pathways in environmental stress response and antifungal drug sensitivity in Cryptococcus neoformans.
-
Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.
-
Cost-effectiveness considerations in the treatment of essential thrombocythemia.
-
Detailed mechanism of the autoxidation of N-hydroxyurea catalyzed by a superoxide dismutase mimic Mn(III) porphyrin: formation of the nitrosylated Mn(II) porphyrin as an intermediate.
-
Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease.
-
Distribution of repair-incorporated nucleotides and nucleosome rearrangement in the chromatin of normal and xeroderma pigmentosum human fibroblasts.
-
Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia.
-
Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
-
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
-
Enalapril and hydroxyurea therapy for children with sickle nephropathy.
-
Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia.
-
Evidence gaps in the management of sickle cell disease: A summary of needed research.
-
Fertility challenges for women with sickle cell disease.
-
Full activation of p34CDC28 histone H1 kinase activity is unable to promote entry into mitosis in checkpoint-arrested cells of the yeast Saccharomyces cerevisiae.
-
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma.
-
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
-
Hormonal control of oviduct growth and differentiation.
-
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
-
Hydroxyurea for Sickle Cell Disease: Now Is the Time!
-
Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
-
Hydroxyurea for the treatment of sickle cell disease.
-
Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children.
-
Hydroxyurea synchronization increases mitotic yield in human glioma cell lines.
-
Hydroxyurea: specific therapy for sickle cell anemia?
-
Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA.
-
Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease.
-
Impact of hydroxyurea on perioperative management and outcomes in children with sickle cell anemia.
-
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
-
Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study.
-
Is low dose hydroxyurea the solution to the global epidemic of sickle cell disease?
-
Leukotriene modifier use and asthma severity: how is a new medication being used by adults with asthma?
-
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
-
Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease.
-
Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis.
-
Management of Sickle Cell Disease in Children.
-
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
-
Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial.
-
NIH consensus development statement on hydroxyurea treatment for sickle cell disease.
-
NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea.
-
National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.
-
Neurofibromatosis type 2.
-
Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial.
-
PINA is essential for growth and positively influences NIMA function in Aspergillus nidulans.
-
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
-
Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease.
-
Pediatric hematology providers' contraceptive practices for female adolescents and young adults with sickle cell disease: A national survey.
-
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
-
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy.
-
Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia.
-
Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors.
-
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
-
Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea.
-
Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer.
-
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
-
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
-
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
-
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
-
Pregnancy outcomes with hydroxyurea use in women with sickle cell disease.
-
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
-
Protein phosphatase 2A-dependent dephosphorylation of replication protein A is required for the repair of DNA breaks induced by replication stress.
-
Protein phosphatase 5 is required for ATR-mediated checkpoint activation.
-
Pulmonary hypertension and nitric oxide depletion in sickle cell disease.
-
Regression supports two mechanisms of fork processing in phage T4.
-
Regulation of translation and transcription of messenger RNA during early embryonic development.
-
Replication of the Escherichia coli chromosome in RNase HI-deficient cells: multiple initiation regions and fork dynamics.
-
Selection and analysis of spontaneous reciprocal mitotic cross-overs in Saccharomyces cerevisiae.
-
Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.
-
Sequential development of human herpes virus 8-positive diffuse large B-cell lymphoma and chronic myelomonocytic leukemia in a 59 year old female patient with hemoglobin SC disease.
-
Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
-
Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy.
-
Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.
-
Tackling adherence in sickle cell disease with mHealth.
-
The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease
-
The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis.
-
The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial.
-
The human oncoprotein and chromatin architectural factor DEK counteracts DNA replication stress.
-
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.
-
The role of actin in spindle orientation changes during the Saccharomyces cerevisiae cell cycle.
-
Treatment choices in chronic myelogenous leukemia.
-
Treatment of high risk or recurrent meningiomas with hydroxyurea.
-
Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
-
What does it mean to be affiliated with care?: Delphi consensus on the definition of "unaffiliation" and "specialist" in sickle cell disease.
-
Keywords of People